Literature DB >> 8543555

Ribozymes: from mechanistic studies to applications in vivo.

J Ohkawa1, T Koguma, T Kohda, K Taira.   

Abstract

The hammerhead ribozyme belongs to the class of molecules known as antisense RNAs. However, because of short extra sequences that form the so-called catalytic loop, it can act as an enzyme. Since the catalytic domain captures magnesium ions and magnesium ions can cleave phosphodiester bonds, hammerhead ribozymes are recognized as metalloenzymes. In general, the cleavage of phosphodiester bonds involves acid/base catalysis, with proton transfer occurring in the transition state. When the possibility of such a proton-transfer process was examined by measuring solvent isotope effects, it became apparent that no proton transfer occurs in the transition state during reactions catalyzed by a hammerhead ribozyme. It is likely, therefore, that hammerhead ribozymes exploit the general double-metal-ion mechanism of catalysis, with Mg2+ ions coordinating directly with the attacking and leaving oxygen moieties. Since the hammerhead ribozyme is one of the smallest RNA enzymes known and has potential as an antiviral agent, thus ribozyme has been extensively investigated for applications in vivo. Ribozymes are described that have possible utility as agents against HIV-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543555     DOI: 10.1093/oxfordjournals.jbchem.a124899

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  7 in total

1.  New modalities in oncology: ribozymes.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-07

2.  Intracellular RNA cleavage by the hairpin ribozyme.

Authors:  A A Seyhan; J Amaral; J M Burke
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

3.  Regulation of CAT protein by ribozyme and antisense mRNA in transgenic mice.

Authors:  D L Sokol; R J Passey; A G MacKinlay; J D Murray
Journal:  Transgenic Res       Date:  1998-01       Impact factor: 2.788

4.  Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase.

Authors:  H Kawasaki; J Ohkawa; N Tanishige; K Yoshinari; T Murata; K K Yokoyama; K Taira
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

5.  Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis.

Authors:  Minako Takahashi; Tadao Funato; Yoko Suzuki; Hiroshi Fujii; Keiko Kumura Ishii; Mitsuo Kaku; Takeshi Sasaki
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

6.  Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.

Authors:  Akiko Fukushima; Noboru Fukuda; Yimu Lai; Takahiro Ueno; Mitsuhiko Moriyama; Fumihiro Taguchi; Akifumi Iguchi; Kazushi Shimizu; Kazumichi Kuroda
Journal:  Intervirology       Date:  2009-05-07       Impact factor: 1.763

Review 7.  Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID-19.

Authors:  Seyedeh Hoda Alavizadeh; Maham Doagooyan; Fatemeh Zahedipour; Shima Yahoo Torghabe; Bahare Baharieh; Firooze Soleymani; Fatemeh Gheybi
Journal:  IET Nanobiotechnol       Date:  2022-03-10       Impact factor: 1.847

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.